<DOC>
	<DOCNO>NCT01375049</DOCNO>
	<brief_summary>This open-label , multi-center study pediatric patient age 3 month le 18 year cystic fibrosis ( CF ) newly detect Pseudomonas aeruginosa ( PA ) pulmonary colonization/infection . All eligible participant treat 28-day course Aztreonam Inhalation Solution ( AZLI ) 75 mg 3 time daily . After completion study drug , subject follow Day 196 safety recurrence PA . The primary objective evaluate proportion participant PA-negative culture time point 6-month monitoring period ( Day 196 ) cessation AZLI treatment . Microbiological culture obtain Baseline , Day 28 ( end AZLI treatment ) , Day 56 ( 1 month complete AZLI treatment ) , Day 112 ( 3 month complete AZLI treatment ) , Day 196 ( 6 month complete AZLI treatment ) .</brief_summary>
	<brief_title>Aztreonam Lysine Pseudomonas Infection Eradication Study</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Males female age 3 month le 18 year Diagnosis CF determine 1997 CF Consensus Conference criterion : Documented sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis test OR Abnormal nasal transepithelial potential difference test OR Two wellcharacterized , diseasecausing genetic mutation CF transmembrane conductance regulator ( CFTR ) gene AND One clinical feature consistent CF Documented new onset positive low respiratory tract culture ( e.g. , throat swab , sputum , BAL ) PA within 30 day study entry ( prior screen visit ) define either first lifetime document PApositive culture OR PA recover least 2 year history PAnegative respiratory culture ( least 2 culture per year ) Forced expiratory volume 1 second ( FEV1 ) ≥ 80 % predict screening visit ( subject ≥ 6 year age ) Clinically stable evidence significant respiratory symptom , obtain clinical evaluation , chest radiograph finding screen would require administration IV antipseudomonal antibiotic , oxygen supplementation , hospitalization . All sexually active female childbearing potential must agree use highly effective method contraception heterosexual intercourse throughout study . Females utilize hormonal contraceptive birth control method must use method least 3 month prior study drug dosing . Males must agree use barrier contraception ( condom spermicide ) heterosexual intercourse screen study completion 90 day last dose study investigational medicinal product Participants and/or parent/guardian must able give write informed consent prior study related procedure Use IV inhale antipseudomonal antibiotic within 2 year study entry ( screen visit ) Use oral antipseudomonal antibiotic within 30 day study entry ( screen visit ) History sputum throat swab culture yield Burkholderia spp . within 2 year prior screen visit History local systemic hypersensitivity monobactam antibiotic History intolerance inhale short act beta 2 agonist History lung transplantation History AZLI ( Cayston® ) administration Administration investigational drug device within 28 day prior screen visit within 6 halflives investigational drug ( whichever longer ) Current use oral corticosteroid dos exceed equivalent 10 mg prednisone per day 20 mg prednisone every day Current requirement daily continuous oxygen supplementation requirement 2 L/minute night Hospitalization pulmonaryrelated illness within 28 day prior screen visit Changes initiation chronic azithromycin treatment within 28 day prior screen visit Changes antimicrobial , bronchodilator ( BD ) , corticosteroid , dornase alfa , hypertonic saline medication within 7 day prior screen visit ; participant stable regimen hypertonic saline ( 28 day on/28 day ) , begin end cycle hypertonic saline allow Changes physiotherapy technique schedule within 7 day prior screen visit Abnormal renal hepatic function result recent test within previous 12 month , define : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ( ULN ) , Serum creatinine &gt; 2 time ULN age Pregnant lactating female ; negative urine pregnancy test require female childbearing potential ( unless surgically sterile ) , confirmatory serum pregnancy test event initial positive urine test result Any serious active medical psychiatric illness ( include drug alcohol abuse ) , opinion investigator , would interfere treatment , assessment , compliance protocol Presence condition abnormality would compromise patient 's safety quality study data , opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>PA</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>AZLI</keyword>
	<keyword>aztreonam</keyword>
</DOC>